The eosinophilic esophagitis (EoE) market in the US was valued at $156.7 million in 2020. The market is projected to grow at a CAGR of more than 25% during the forecast period. The COVID-19 pandemic did not impact the EoE market in 2020. Although the uptake of high-priced biologics is expected to be slow, they are expected to capture significant growth revenue over the next 10 years.
A large number of symptomatic treatments are currently used off-label. The most frequently used drug classes are proton pump inhibitors and corticosteroids. The most commonly used off-label proton pump inhibitors for EoE are omeprazole and pantoprazole. The most commonly corticosteroids used off-label for EoE are budesonide and fluticasone propionate. The greatest unmet needs within the EoE market are lack of data, more effective or curative therapies, increased awareness and education, and more options for the pediatric population.
Overview of the eosinophilic esophagitis market
For more insights, download a free sample
What are the market dynamics in the eosinophilic esophagitis market?
EoE is still a relatively poorly understood entity. Increasing emphasis has been placed on the role of food allergy but development of eosinophilic esophagitis may be multifactorial, with contributing factors including inflammatory mediators, genetic susceptibility, environmental factors, atopic conditions, dietary products, esophageal microbiome, and oral immunotherapy.
The pathogenesis of EoE is unknown. However, it likely results from an interplay of genetics, the immune system, environmental factors, and mechanisms of mucosal damage and fibrosis. EoE is associated with T helper cell-2 (Th2) type immune responses, similar to other atopic conditions. The endoscopic assessment of the esophagus has shown elevated levels of the Th2 cytokines interleukin (IL)-4, IL-5, and IL-13, as well as mast cells, in the esophageal mucosal biopsies of EoE patients
The sales of high-priced biologics represent the most impactful driver of growth for the EoE market. The launch of Dupixent (dupilumab) for pediatrics, adolescents, and adults is expected to increase the sales significantly. Also, low diagnosis rates caused by limited disease awareness will continue to keep the diagnosed cases at a low rate.
What are the key drugs used in the eosinophilic esophagitis market?
Off- label PPIs (omeprazole, pantoprazole), Off- label GRAs (budesonide and fluticasone propionate), Eohila (budesonide), APT- 1011 (fluticasone propionate), Cendakimab (RPC- 4046), Fasenra (benralizumab), and Dupixent (dupilumab) are the key drugs used in the eosinophilic esophagitis market.
By 2030, the EoE market is expected to have a flood of marketed drugs. Reformulations of budesonide and fluticasone propionate are expected to receive FDA approval and launch as Eohilia and APT-1011, respectively. Additionally, innovative entrants such as cendakimab (RPC-4046), Fasenra (benralizumab), and Dupixent (dupilumab) are expected to gain positions in the EoE market.
Eosinophilic esophagitis market, by drug type
For more drug type insights, download a free sample
What is the overview of eosinophilic esophagitis market?
The EoE pipeline consists of 11 drugs across all stages of development, with five drugs expected to launch in the forecast period (APT-1011, Eohilia, Dupixent, Fasenra, and cendakimab).
Eight out of 10 pipeline agents are first-in-class drugs with novel mechanisms of action to the EoE market, including interleukin inhibitors (IL-13, IL-4, and IL-5 receptor subunit alpha inhibitors), a mast cell stabilizer, a sphingosine 1-phosphate receptor agonist, an anti-inflammatory, an allergen desensitization immunotherapy, and a lanthionine synthetase component c-like protein 2agonist.
Which are the key companies in the eosinophilic esophagitis market?
Takeda Pharmaceuticals, Ellodi Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals (Sanofi), Allakos Inc, Arena Pharmaceuticals, Revolo Biotherapeutics, DBV Technologies, and Landos Biopharma are the key companies in the eosinophilic esophagitis market.
Eosinophilic esophagitis market, by key companies
For more key company insights, download a free sample
Market report scope
|Market size in the US (2020)||$156.7 million|
|Key drugs||Off- label PPIs (omeprazole, pantoprazole), Off- label GRAs (budesonide and fluticasone propionate), Eohila (budesonide), APT- 1011 (fluticasone propionate), Cendakimab (RPC- 4046), Fasenra (benralizumab), and Dupixent (dupilumab)|
|Key companies||Takeda Pharmaceuticals, Ellodi Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals (Sanofi), Allakos Inc, Arena Pharmaceuticals, Revolo Biotherapeutics, DBV Technologies, and Landos Biopharma|
This report provides an overview of eosinophilic esophagitis. The report includes:
- Overview of EoE including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline EoE market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting EoE therapeutics sales in the US.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the US EoE therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the US EoE therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US EoE market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the US EoE therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Bristol Myers Squibb
Regeneron Pharmaceuticals (Sanofi)
Table of Contents
1 Table of Contents (PowerPoint Deck)
1 Executive Summary
1.1 Executive Summary
2 Disease Overview
2.1 Overview of Eosinophilic Esophagitis
2.2 Eosinophilic Esophagitis SWOT Analysis
3.1 Lifetime Diagnosed Prevalent Cases of EoE, All Ages, Both Sexes, 2020–2030
3.2 Sources and Methodology for Lifetime Diagnosed Prevalent Cases of EoE
4 Current Treatment Options
4.1 Treatment Paradigm
4.2 Treatment Algorithm
4.3 Marketed Products
4.4 Product Profile: Proton Pump Inhibitors
4.5 Product Profile: Glucocorticoid Receptor Agonists
5 Unmet Needs and Opportunities
5.1 Lack of Data
5.2 More Effective or Curative Therapies
5.3 Increased Awareness and Education
5.4 Treatment Options for the Pediatric Population
6 Pipeline Assessment
6.1 Eosinophilic Esophagitis Pipeline Overview
6.2 Leading Pipeline Agents
6.3 Product Profile: Takeda Pharmaceutical’s Eohilia (budesonide)
6.4 Product Profile: Ellodi Pharmaceuticals’ APT-1011 (fluticasone propionate)
6.5 Product Profile: Bristol Myers Squibb’s Cendakimab (RPC-4046)
6.6 Product Profile: AstraZeneca’s Fasenra (benralizumab)
6.7 Product Profile: Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab)
6.8 Product Profile: Allakos’ Lirentelimab (AK-002)
7 R&D Strategies
7.1 Trends in Clinical Trial Design in Eosinophilic Esophagitis
7.2 FDA Treatment Guidance for Industry – EoE
7.3 Trends in Deal-Making in Eosinophilic Esophagitis
8 Market Outlook
8.1 Eosinophilic Esophagitis Market Forecast
8.2 Impact of COVID-19 on Eosinophilic Esophagitis
8.3 Market Drivers and Barriers
9.2 Primary Research: KOL Information
9.3 About the Authors
10 Contact Us
Frequently Asked Questions
The eosinophilic esophagitis market in the US was valued at $156.7 million in 2020.
Off- label PPIs (omeprazole, pantoprazole), Off- label GRAs (budesonide and fluticasone propionate), Eohila (budesonide), APT- 1011 (fluticasone propionate), Cendakimab (RPC- 4046), Fasenra (benralizumab), and Dupixent (dupilumab) are the key drug types used in the eosinophilic esophagitis market.
Takeda Pharmaceuticals, Ellodi Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals (Sanofi), Allakos Inc, Arena Pharmaceuticals, Revolo Biotherapeutics, DBV Technologies, and Landos Biopharma are some of the key companies in the eosinophilic esophagitis market.
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.